Northera ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3

6. パーキンソン病

---

臨床試験数 : 2,307 /  薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04510922 (ClinicalTrials.gov)	February 11, 2019	9/7/2020	Lundbeck TOMs Orthostatic Hypotension	Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study	Orthostatic Hypotension;Idiopathic Parkinson Disease	Drug: Droxidopa 100 MG [Northera]	Alberto Espay, MD, MSc	Lundbeck LLC	Completed	30 Years	80 Years	All	10	Phase 4	United States
2	NCT03034564 (ClinicalTrials.gov)	January 2017	25/1/2017	A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease	A Randomized, Double-Blind, Placebo-Controlled Study of Droxidopa for Fatigue in Parkinson's Disease	Parkinson Disease;Fatigue;Parkinsonism	Drug: Northera;Drug: Placebo Oral Tablet	The Cooper Health System	NULL	Terminated	18 Years	N/A	All	1	Phase 4	United States
3	NCT02812147 (ClinicalTrials.gov)	May 2016	25/5/2016	Effect of L-Dihydoxyphenylserine on Locomotion, Postural Stability, and Fall Risk Reduction in Parkinson Disease	Effect of L-Dihydoxyphenylserine (L-DOPS, Northera) a Central and Peripheral Norepinephrine Agent on Locomotion, Postural Stability (Balance), and Fall Risk Reduction in Parkinson Disease (PD)	Parkinson Disease	Drug: L-DOPS;Drug: Placebo	St. Joseph's Hospital and Medical Center, Phoenix	Arizona State University, Tempe	Active, not recruiting	30 Years	83 Years	All	20	Phase 2	United States